Company: PTPI
Filing Date: 2025-02-14
Form Type: S-1/A
Source: 0001410578-25-000137
Chunk: 2

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-14
Form: S-1/A
Chunk 2
---
 stock, $0.0001 par value per share (“common stock”), and an accompanying Series A warrant (the “Series A Warrants”) to purchase 0.25 share of common stock and an accompanying Series B warrant to purchase one share of common stock (the “Series B Warrants”, and, with the Series A Warrants, the “Series Warrants”), at the assumed public offering price of $0.2475 per Unit, which was the last reported sales price of our common stock on The Nasdaq Capital Market on February 13, 2025. The Units have no stand-alone rights and will not be certificated or issued as stand-alone securities. The exercisability of the Series Warrants will be available only upon receipt of such stockholder approval as may be required by the applicable rules and regulations of the Nasdaq Capital Market, including, but not limited to, with respect to (i) the issuance of all of the shares of common stock issuable upon exercise the Series Warrants in accordance with their terms (including adjustment provisions set forth therein), and (ii) to consent to any adjustment to the exercise price or number of shares of common stock underlying the Series Warrants in the event of a Share Combination Event and Dilutive Issuance (collectively, the “Warrant Stockholder Approval”). We have agreed to use our reasonable best efforts to obtain such approval within 60 days from the closing of this offering, and agreed to cause an additional stockholder meeting to be held every ninety days thereafter until (i) such Stockholder Approval is obtained. We cannot assure you that we will be able to obtain requisite Stockholder Approval. Each Series A Warrant offered hereby will become exercisable beginning on the first trading day following the date of Warrant Stockholder Approval (the “Initial Exercise Date”) at an exercise price of $ per share of common stock and will expire five years from the date of the Initial Exercise Date. Each Series B Warrant offered hereby will become exercisable beginning on the Initial Exercise Date at an exercise price of $ per share of common stock and will expire on the one (1) year anniversary of the Initial Exercise Date. Holders the Series B Warrants may effect an “alternative cashless exercise” at any time while the Series B Warrants are outstanding following the Initial Exercise Date. Under the alternative cashless exercise option, a holder of a Series B Warrant has the right to receive an aggregate number of shares equal to the product of (i) the aggregate number of shares of